KEGG   DRUG: EmicizumabHelp
Entry
D10821                      Drug                                   

Name
Emicizumab (USAN/INN);
Emicizumab (genetical recombination) (JAN);
Hemlibra (TN)
Product
Formula
C2164H3334N572O690S18
Exact mass
48949.8354
Mol weight
48980.2152
Sequence
(Heavy chain1:H)
QVQLVESGGG LVQPGGSLRL SCAASGFTFS YYDIQWVRQA PGKGLEWVSS ISPSGQSTYY
RREVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRT GREYGGGWYF DYWGQGTLVT
VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TQTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQKE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QEGNVFSCSV MHEALHNRYT QKSLSLSP
(Heavy chain2:h)
QVQLVQSGSE LKKPGASVKV SCKASGYTFT DNNMDWVRQA PGQGLEWMGD INTRSGGSIY
NEEFQDRVIM TVDKSTDTAY MELSSLRSED TATYHCARRK SYGYYLDEWG EGTLVTVSSA
STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQYNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQEGN
VFSCSVMHEA LHNHYTQESL SLSP
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASRNIE RQLAWYQQKP GQAPELLIYQ ASRKESGVPD
RFSGSRYGTD FTLTISSLQP EDIATYYCQQ YSDPPLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(disulfide bridges: H22-H96, H137-L214, H150-H206, H229-h225, H232-h228, H264-H324, H370-H428, h22-h96, h133-L'214, h146-h202, h260-h320, h366-h424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Remark
Therapeutic category: 6349
ATC code: B02BX06
Product: D10821<JP/US>
Efficacy
Bleeding suppressant, Factor VIII replacement
Comment
Monoclonal antibody
Preventing bleeding in adults and children with hemophilia A
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BX Other systemic hemostatics
     B02BX06 Emicizumab
      D10821  Emicizumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   634  Human blood preparations
    6349  Others
     D10821  Emicizumab (USAN/INN); Emicizumab (genetical recombination) (JAN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10821
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10821
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10821
BRITE hierarchy
Other DBs
CAS: 1610943-06-0
PubChem: 319902621
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system